| Name | Title | Contact Details |
|---|
Vicus Therapeutics is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nirvana Center Dispensaries offers recreational and medical marijuana in Arizona, Michigan and Maryland. We strive to provide the highest quality cannabis products and friendly, knowledgeable service to our patients & customers.
Connections Health Solutions, LLC is the pioneer of behavioral health crisis care. The Company operates the two largest behavioral health crisis facilities in the nation and provides a range of services to help stabilize and treat people with mental health and substance use diagnoses. Connections` model emphasizes providing treatment in the least restrictive setting and has demonstrated improved quality and cost savings, including significantly reducing hospital admissions in Medicaid and behavioral health populations. For more information and crisis resources, please visit www.connectionshs.com. We believe that people do best when they don`t have to wait a long time to get what they need. As a result, we have created a culture in which we welcome everyone regardless of clinical complexity, provide intervention as quickly as possible, and partner with community support systems to maximize recovery. Our corporate mission is simple: to address any behavioral health need, at any time.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Outlook Associates, Inc. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.